Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TG Therapeutics, Inc.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a previously approved protocol.
Subjects must have completed at least 6 cycles of therapy on their current protocol.
You may not be if
Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while participating in their immediate previous trial.
Clareo Health | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
